MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

Search

ENANTA PHARMACEUTICALS INC

Deschisă

SectorSănătate

10.64 2.11

Rezumat

Modificarea prețului

24h

Curent

Minim

10.07

Maxim

10.72

Indicatori cheie

By Trading Economics

Venit

4.4M

-18M

Vânzări

3.4M

18M

Marjă de profit

-99.678

Angajați

131

EBITDA

5.6M

-15M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+72.76% upside

Dividende

By Dow Jones

Următoarele câștiguri

24 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

185M

324M

Deschiderea anterioară

8.53

Închiderea anterioară

10.64

Sentimentul știrilor

By Acuity

35%

65%

104 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

ENANTA PHARMACEUTICALS INC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 oct. 2025, 23:30 UTC

Acțiuni populare

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 oct. 2025, 21:21 UTC

Câștiguri

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 oct. 2025, 00:00 UTC

Achiziții, Fuziuni, Preluări

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 oct. 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 oct. 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 oct. 2025, 23:29 UTC

Achiziții, Fuziuni, Preluări

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 oct. 2025, 23:29 UTC

Achiziții, Fuziuni, Preluări

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 oct. 2025, 23:29 UTC

Achiziții, Fuziuni, Preluări

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 oct. 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 oct. 2025, 22:54 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Scales's JV Buyout Lauded by Bull -- Market Talk

2 oct. 2025, 22:54 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Global Forex and Fixed Income Roundup: Market Talk

2 oct. 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 oct. 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 oct. 2025, 21:17 UTC

Achiziții, Fuziuni, Preluări

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 oct. 2025, 20:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Energy & Utilities Roundup: Market Talk

2 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 oct. 2025, 20:49 UTC

Achiziții, Fuziuni, Preluări

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 oct. 2025, 20:00 UTC

Achiziții, Fuziuni, Preluări

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 oct. 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 oct. 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 oct. 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 oct. 2025, 18:46 UTC

Achiziții, Fuziuni, Preluări

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 oct. 2025, 18:46 UTC

Achiziții, Fuziuni, Preluări

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 oct. 2025, 18:46 UTC

Achiziții, Fuziuni, Preluări

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 oct. 2025, 18:45 UTC

Achiziții, Fuziuni, Preluări

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 oct. 2025, 18:45 UTC

Achiziții, Fuziuni, Preluări

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 oct. 2025, 18:44 UTC

Achiziții, Fuziuni, Preluări

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 oct. 2025, 18:44 UTC

Achiziții, Fuziuni, Preluări

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 oct. 2025, 18:44 UTC

Achiziții, Fuziuni, Preluări

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 oct. 2025, 18:43 UTC

Achiziții, Fuziuni, Preluări

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Comparație

Modificare preț

ENANTA PHARMACEUTICALS INC Așteptări

Obiectiv de preț

By TipRanks

72.76% sus

Prognoză pe 12 luni

Medie 18.33 USD  72.76%

Maxim 25 USD

Minim 9 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruENANTA PHARMACEUTICALS INC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

5

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.04 / 5.44Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

104 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
help-icon Live chat